2 Stocks That Could Capitalize on the GLP-1 Boom

CVS Health highlights improved momentum plus GLP-1 access initiatives: Q2 revenue rose 7.3% YoY to $106.1B and adjusted EPS increased 42.5% YoY to $2.58, supported by offering all approved U.S. GLP-1s and low-cost $29 online eligibility visits. Roche, meanwhile, reports H1 revenue of 30.4B CHF ($37.8B), down 2% reported but up 6% in constant currency, with EPS of 10.85 CHF ($13.5) up 9% in constant currency. Roche’s investigational CT-388 in a phase 2 study delivered up to 22.5% mean weight loss at 48 weeks (placebo-adjusted) and is now in phase 3, positioning it to potentially lead in GLP-1/obesity if successful.

Analysis

CVS is the cleaner near-term beneficiary, but not because it captures the drug economics; the edge is patient routing. If GLP-1 access broadens, the incremental value comes from pulling patients into an integrated channel where screening, fulfillment, adherence, and refill persistence can be monetized across pharmacy and care-management, not from a big step-up in script gross margin. The market may still underprice how much a higher-traffic obesity franchise can improve same-store mix and reduce customer churn in Caremark over 1-3 quarters.

The catch is that GLP-1 utilization is still payer-gated, so the upside is constrained unless coverage expands. Prior auth, supply normalization, and rebate pressure can all convert a volume story into a low-margin administrative win; that would leave CVS with more activity but limited earnings power. For Roche, the obesity pipeline is a 6-18 month option, not a current driver: phase 3 success could add a meaningful rerating, but until data de-risks, the stock remains anchored by its core portfolio and not the GLP-1 narrative.

Contrarian view: consensus is probably overestimating how quickly GLP-1 access translates into profits for intermediaries and underestimating how much value accrues to the manufacturers with scale and manufacturing execution. The better setup is to own the enablers only where they already have distribution leverage; otherwise the trade is mostly a sentiment overlay. What would falsify the CVS thesis is a lack of script acceleration or margin dilution in pharmacy/benefit services over the next two quarters; for Roche, it is any phase 3 signal that fails to match Lilly-class efficacy or tolerability.

Key Decisions for Investors

• Modest long CVS on pullbacks for a 1-3 month horizon; thesis is traffic and retention, not drug-margin capture. Risk/reward is attractive only if upcoming quarter commentary shows improving pharmacy mix and no reimbursement-driven margin leakage.
• Keep Roche (RHHBY) on a watch list rather than forcing a position until CT-388 phase 3 data is visible. Treat it as a 6-18 month optionality trade; a clean positive readout could rerate the obesity pipeline, while failure leaves the stock reliant on core pharma/diagnostics.
• Avoid chasing Lilly/Novo on the access headline alone; broader access helps volume, but the incremental economic upside is likely already embedded in their premium multiples. Falsifier for this caution would be a material acceleration in U.S. coverage and prescriptions without offsetting pricing pressure.
• If taking a relative-value view, prefer CVS vs weaker standalone pharmacy operators for a 3-6 month window. CVS has the integrated payer/pharmacy data loop to convert GLP-1 demand into higher stickiness; a clean miss in prescription growth would invalidate the trade.